228 related articles for article (PubMed ID: 15589593)
1. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma.
Tate S; Hirai Y; Takeshima N; Hasumi K
Gynecol Oncol; 2005 Jan; 96(1):143-9. PubMed ID: 15589593
[TBL] [Abstract][Full Text] [Related]
2. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic value of serum CA(125) level change during chemotherapy post-surgery in patients with advanced epithelial ovarian carcinoma].
Lan CY; Huang H; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):732-6. PubMed ID: 19087537
[TBL] [Abstract][Full Text] [Related]
4. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between CA125 half life during neoadjuvant chemotherapy and the optimal operation rate and prognosis in patients with advanced epithelial ovarian carcinoma].
Xi XW; Wan XP; Li SD; Sun TW; Zhu YP
Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):91-4. PubMed ID: 16640855
[TBL] [Abstract][Full Text] [Related]
6. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Hopkins L; Faught W; Fung-Kee-Fung M
Gynecol Oncol; 2007 Jun; 105(3):712-5. PubMed ID: 17400284
[TBL] [Abstract][Full Text] [Related]
7. [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
Yang R; Feng J; Fang XZ; Bai F; Cheng YX; Liu C; Zhu W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):459-63. PubMed ID: 17083811
[TBL] [Abstract][Full Text] [Related]
8. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
9. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
10. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
Markman M; Federico M; Liu PY; Hannigan E; Alberts D
Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Alshaikh G; Hopkins L; Faught W; Fung MF
Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146
[TBL] [Abstract][Full Text] [Related]
12. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
Gadducci A; Zola P; Landoni F; Maggino T; Sartori E; Bergamino T; Cristofani R
Gynecol Oncol; 1995 Jul; 58(1):42-7. PubMed ID: 7789889
[TBL] [Abstract][Full Text] [Related]
13. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
15. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
16. [Prognosis and prognostic factor analysis epithelial ovarian cancer].
Wen H; Sun W; Guo Y
Zhonghua Fu Chan Ke Za Zhi; 1997 Mar; 32(3):159-62. PubMed ID: 9596891
[TBL] [Abstract][Full Text] [Related]
17. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract][Full Text] [Related]
18. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
[TBL] [Abstract][Full Text] [Related]
19. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
Bădulescu F; Bădulescu A; Schenker M; Popescu CF; Stoica Z
Rom J Morphol Embryol; 2005; 46(4):329-34. PubMed ID: 16688372
[TBL] [Abstract][Full Text] [Related]
20. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]